Feedback

Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma

Affiliation
Department of General Surgery ,Longquan People’s Hospital ,Lishui ,China
Wang, Gui;
Affiliation
Department of Breast Surgery ,First Affiliated Hospital of Wenzhou Medical University ,Wenzhou ,China
Yang, Chenghui;
Affiliation
Department of General Surgery ,Longquan People’s Hospital ,Lishui ,China
Zeng, Donglin;
Affiliation
Department of General Surgery ,Longquan People’s Hospital ,Lishui ,China
Wang, Jihao;
Affiliation
Department of General Surgery ,Longquan People’s Hospital ,Lishui ,China
Mao, Huaxin;
Affiliation
Department of General Surgery ,Longquan People’s Hospital ,Lishui ,China
Xu, Yu;
Affiliation
Academy of Chinese Medical Sciences ,Zhejiang Chinese Medical University ,Hangzhou ,China
Jiang, Chao;
Affiliation
Department of Breast Surgery ,Second Affiliated Hospital ,Zhejiang University School of Medicine ,Hangzhou ,China
Wang, Zhen

Background: Breast squamous cell carcinoma (SCC) is an uncommon and highly aggressive variant of metaplastic breast cancer. Despite its rarity, there is currently no consensus on treatment guidelines for this specific subtype. Previous studies have demonstrated that chemotherapy alone has limited efficacy in treating breast SCC. However, the potential for targeted therapy in combination with chemotherapy holds promise for future treatment options. Case presentation: In this case report, we present a patient with advanced HER2-positive breast SCC, exhibiting a prominent breast mass, localized ulcers, and metastases in the lungs and brain. Our treatment approach involved the administration of HER2-targeted drugs in conjunction with paclitaxel, resulting in a sustained control of tumor growth. Conclusion: This case represents a rare occurrence of HER2-positive breast SCC, with limited available data on the efficacy of previous HER2-targeted drugs in treating such patients. Our study presents the first application of HER2-targeted drugs in this particular case, offering novel therapeutic insights for future considerations. Additionally, it is imperative to conduct further investigations to assess the feasibility of treatment options in a larger cohort of patients.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2024 Wang, Yang, Zeng, Wang, Mao, Xu, Jiang and Wang.

Use and reproduction: